112197-16-7

Basic information

• Product Name: 3-Pyridinemethanol,2-methoxy-(9CI)
• Synonyms: 3-Pyridinemethanol,2-methoxy-(9CI);(2-Methoxy-3-pyridinyl)methanol;(2-Methoxypyridin-3-yl)methanol;3-Hydroxymethyl-2-methoxypyridine;2-Methoxypyridine-3-methanol;(2-Methoxypyridin-3-yl);3-Pyridinemethanol, 2-methoxy-
• CAS NO: 112197-16-7
• Molecular Formula: C₇H₉NO₂
• Molecular Weight: 139.153
• Product Categories: PYRIDINE
• Mol File: 112197-16-7.mol

Chemical Properties

• Melting Point: lowmeltsolid°
• Boiling Point: 242℃
• Flash Point: 100℃
• Appearance: /
• Density: 1.155
• Vapor Pressure: 0.019mmHg at 25°C
• Refractive Index: 1.534
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 13.20±0.10(Predicted)
• CAS DataBase Reference: 3-Pyridinemethanol,2-methoxy-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinemethanol,2-methoxy-(9CI)(112197-16-7)
• EPA Substance Registry System: 3-Pyridinemethanol,2-methoxy-(9CI)(112197-16-7)

Safety Data

• RIDADR: UN2811
• HazardClass: IRRITANT
• Hazardous Substances Data: 112197-16-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Pyridinemethanol, 2-methoxy-(9CI) is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs and medications. Its unique chemical structure allows it to be a key component in the creation of various therapeutic agents.
Used in Agricultural Chemicals:
In the agricultural sector, 3-Pyridinemethanol, 2-methoxy-(9CI) serves as an intermediate in the production of agrochemicals, helping to develop effective and safe products for crop protection and enhancement of agricultural yields.
Used as a Flavoring Agent:
3-Pyridinemethanol, 2-methoxy-(9CI) is used as a flavoring agent in the food and beverage industry, adding unique taste profiles to various products. Its ability to enhance flavors makes it a valuable ingredient in the creation of diverse food items.
Used in Fragrance and Flavor Chemicals:
This chemical compound is utilized in the manufacture of fragrance and flavor chemicals, where it contributes to the development of scents and tastes for a wide range of consumer products, including perfumes, cosmetics, and other personal care items.
Used in Personal Care Products:
3-Pyridinemethanol, 2-methoxy-(9CI) is also employed in the production of various personal care products, such as cosmetics, skincare, and hair care items. Its incorporation into these products helps to improve their efficacy and sensory attributes, providing consumers with enhanced experiences.

InChI:InChI=1/C7H9NO2/c1-10-7-6(5-9)3-2-4-8-7/h2-4,9H,5H2,1H3

Upstream product

• 110-88-3 1,3,5-Trioxan 
• 1628-89-3 2-methoxypyridine 
• 67367-26-4 2-methoxynicotinic acid methyl ester 
• 71255-09-9 2-methoxynicotinaldehyde 
• 16498-81-0 2-methoxynicotinic acid 
• 49609-84-9 2-Chloronicotinoyl chloride 
• 2942-59-8 2-chloronicotinic acid 
• 40134-18-7 methyl 2-chloropyridine-3-carboxylate 
• 50-00-0 formaldehyd 
• 163105-90-6 2-methoxypyridin-3-yl-boronic acid 

Downstream Products

• 162046-62-0 2-methoxy-pyridin-3-ylmethyl chloride 
• 1020104-70-4 3-(4'-bromo-biphenyl-4-yloxymethyl)-2-methoxy-pyridine 
• 178982-36-0 2-benzyloxymethyl-5-(3,5-dichlorophenylthio)-4-isopropyl-1-(2-methoxypyridin-3-ylmethyl)-1H-imidazole 
• 1361225-04-8 1,1,1,3,3,3-hexafluoro-2-(4-(2-((2-methoxy-3-pyridinyl)methyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-2-propanol 
• 1361225-05-9 ethyl N-(diphenylmethylidene)-3-(2-methoxy-3-pyridinyl)alaninate 
• 1361225-10-6 2-((2-methoxy-3-pyridinyl)methyl)piperazine 
• 351410-38-3 2-(2-methoxy-3-pyridyl)acetic acid 
• 351410-37-2 (2-methoxypyridin-3-yl)acetonitrile 
• 942060-13-1 3-(bromomethyl)-2-methoxypyridine 
• 42463-41-2 2-hydroxy-3-hydroxymethylpyridine 

Relevant articles and documents

PYRIDINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS

The present disclosure is directed to pyridinone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).

Development of inhibitors against mycobacterium abscessus tRNA (m1G37) Methyltransferase (TrmD) Using Fragment-Based Approaches

Mycobacterium abscessus (Mab) is a rapidly growing species of multidrug-resistant nontuberculous mycobacteria that has emerged as a growing threat to individuals with cystic fibrosis and other pre-existing chronic lung diseases. Mab pulmonary infections are difficult, or sometimes impossible, to treat and result in accelerated lung function decline and premature death. There is therefore an urgent need to develop novel antibiotics with improved efficacy. tRNA (m1G37) methyltransferase (TrmD) is a promising target for novel antibiotics. It is essential in Mab and other mycobacteria, improving reading frame maintenance on the ribosome to prevent frameshift errors. In this work, a fragment-based approach was employed with the merging of two fragments bound to the active site, followed by structure-guided elaboration to design potent nanomolar inhibitors against Mab TrmD. Several of these compounds exhibit promising activity against mycobacterial species, including Mycobacterium tuberculosis and Mycobacterium leprae in addition to Mab, supporting the use of TrmD as a target for the development of antimycobacterial compounds.

ISOQUINOLINES AS INHIBITORS OF HPK1

Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibitng HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.

Modular Route to Azaindanes

A convergent radical based route to azaindanes is described, relying on the degenerative addition transfer of various substituted S-(pyridylmethyl)-O-ethyl dithiocarbonates (xanthates) to functional alkenes followed by radical cyclization onto the pyridine ring activated by protonation with trifluoroacetic acid. In one case, a richly decorated cyclohepta[b]pyridine could be assembled swiftly by allowing the first adduct to N-phenylmaleimide to undergo addition to N-allylphthalimide prior to cyclization.

Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of sulphone-based CRTh2 antagonists

Monocyclic and bicyclic ring systems were investigated as the "core" section of a series of diphenylsulphone-containing acetic acid CRTh2 receptor antagonists. A range of potencies were observed and single-digit nanomolar potencies were obtained in both the monocyclic and bicyclic cores. Residence times for the monocyclic compounds were very short. Some of the bicyclic cores displayed better residence times. A methyl group in the northern part of the core, between the head and tail was a necessary requirement for the beginnings of long residence times. Variations of the tail substitution maximised potencies and residence times.

HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME

Disclosed are compounds of formula (I): or a pharmaceutically acceptable salt thereof; wherein Y, Ra, Ra', Rc, Rf, X2, Rd, Rd', Re, Re', m, and G have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry, useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular and neurodegenerative diseases or disorders.

Palladium-catalyzed arylation of aldehydes with bromo-substituted 1,3-diaryl-imidazoline carbene ligand

The combination of 0 valent palladium precursor and bromo-substituted 1,3-diaryl-imidazoline carbene ligand precursor such as 1-(2-bromophenyl)-3-(2,6-diisopropylphenyl)-imidazolinium chloride 1a exhibited high catalytic activity for the 1,2-addition of arylboronic acids to aldehydes including aqueous formaldehyde.

SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES

The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS

This invention provides novel heterocyclic derived matrix metalloprotease inhibitors of the formula: and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing matrix metalloproteases. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.

Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs)

Several classes of arylsulfone-based MMP-2/-9 inhibitors utilizing 6- to 8-membered heterocyclic rings as zinc-binding groups (ZBGs) have been synthesized and their enzyme inhibitory activities were evaluated. Although a number of 6- and 7-membered hetero